8-KEarnings & ResultsCorporate ChangesExhibits & Filings

ELI LILLY & Co 8-K Report, Financial Results (Oct 21, 2010)

Filed October 21, 2010For Securities:LLY

Summary

Eli Lilly and Company (LLY) filed an 8-K report on October 20, 2010, detailing events that occurred around October 18-21, 2010. A key aspect of this filing is the announcement of the company's third-quarter and nine-month financial results for 2010, released on October 21, 2010. The company provided both GAAP and non-GAAP financial measures in its earnings release, highlighting adjustments for items such as in-process R&D charges, restructuring costs, and settlement charges related to Zyprexa. Investors are informed about the company's rationale for using non-GAAP measures, which is to offer a clearer view of ongoing operations and facilitate meaningful period-over-period comparisons. Furthermore, the report disclosed significant amendments to the company's Bylaws, effective October 18, 2010. These amendments introduce new, more stringent requirements for shareholders intending to propose business or nominate directors at annual meetings. These include extended notice periods, enhanced disclosure obligations regarding stock holdings and potential conflicts, and requirements for nominees to submit questionnaires and representations. Additionally, the Bylaws were updated regarding indemnification provisions for directors and officers, including changes to the definition of a 'Change in Control' which now requires a higher threshold of stock ownership (20% vs. 15%) and a reduced proportion of continuing directors on the board to trigger such a change.

Key Highlights

  • 1Eli Lilly announced its Q3 and nine-month 2010 financial results on October 21, 2010, via a press release.
  • 2The company utilized both GAAP and non-GAAP financial reporting, with non-GAAP measures adjusted for specific charges to provide insights into ongoing operations.
  • 3Adjustments to non-GAAP figures included in-process R&D, restructuring charges, and previous settlement costs related to Zyprexa.
  • 4The filing includes revised Bylaws, effective October 18, 2010, which impose stricter requirements for shareholder proposals and director nominations.
  • 5Shareholder proposals and director nominations now require earlier notice (180 days prior) and more extensive disclosures about holdings and arrangements.
  • 6Amendments to indemnification provisions include a higher threshold (20%) for a 'Change in Control' based on stock ownership.
  • 7The definition of 'Change in Control' was also revised to consider the composition of the board of directors, requiring less than half of directors to be 'Continuing Directors'.

Frequently Asked Questions

The primary financial information in this filing pertains to Eli Lilly's third-quarter and nine-month results for 2010, announced via a press release on October 21, 2010. The company provided both GAAP and non-GAAP financial figures, explaining that non-GAAP measures are used to exclude certain volatile or one-time items like R&D charges, restructuring costs, and past legal settlements to offer a clearer view of ongoing operational performance.

Effective October 18, 2010, Eli Lilly amended its Bylaws. Key changes include more stringent requirements for shareholders wishing to propose business or nominate directors at annual meetings. These now involve an earlier notice period (180 days prior), expanded disclosure requirements about share ownership and any agreements related to the company's stock, and updated requirements for director nominees regarding questionnaires and representations.

The definition of 'Change in Control' in the Bylaws has been revised. The threshold for a change in control based on beneficial stock ownership has been increased from 15% to 20%. Additionally, a change in control can now be triggered if less than one-half (previously less than two-thirds) of the board of directors consists of 'Continuing Directors'.

Eli Lilly uses non-GAAP financial measures to provide investors with a clearer understanding of the company's ongoing operational performance. These measures exclude items that are typically difficult to predict and can significantly impact reported results, such as R&D charges, restructuring costs, and legal settlements. The company believes these adjustments facilitate more meaningful period-over-period comparisons and help identify underlying business trends.